Sterling Capital Management’s Enliven Therapeutics ELVN Stock Holding History

Sterling Capital Management’s Portfolio ELVN Stock Details ELVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$10K	Sell	256 -23	-8%	-$637	﹤0.01%	2369
2025 Q4	$4.3K	Buy	279 +177	+174%	+$3.53K	﹤0.01%	2936
2025 Q3	$2.09K	Buy	102 +21	+26%	+$423	﹤0.01%	2970
2025 Q2	$1.63K	Buy	81 +14	+21%	+$265	﹤0.01%	2972
2025 Q1	$1.32K	Sell	67 -28	-29%	-$603	﹤0.01%	2722
2024 Q4	$2.14K	Buy	95 +55	+138%	+$1.43K	﹤0.01%	2768
2024 Q3	$1.02K	Buy	+40	New	+$926	﹤0.01%	2518

Other funds holding ELVN

OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return

Fidelity Investments

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Polar Capital Holdings London, United Kingdom $22.9B AUM 115.26% 1-Year Est. Return

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Citadel Advisors

Citadel Advisors Miami, Florida $141B AUM 30.34% 1-Year Est. Return